PARIS – Bone Therapeutics SA reported results from a phase I/IIa delayed-union fracture study with Allob, its allogeneic cell therapy product.

PARIS – Luxembourg-based Steba Biotech SA is embarking on a series A round to raise $30 million to launch an already approved treatment vascular targeted focal photodynamic therapy (PDT) for early-stage prostate cancer in Europe.